STAT1 and breast carcinoma: This is partially mediated by tyrosine 239/240 and tyrosine 313 residues of Shc1, which activate STAT3-dependent immunosuppression and inhibit STAT1-induced immune surveillance in breast cancer cells, respectively [86].